ICAR Research Data Repository for Knowledge Management
Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis.
IR@CSIR-CFTRI
View Archive Info| Field | Value | |
| Relation |
http://ir.cftri.com/14625/
https://doi.org/10.1007/s10787-019-00618-0 |
|
| Title |
Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis. |
|
| Creator |
Nayana, Venugopal
Pooja, Acharya Ramaprasad, T. R. |
|
| Subject |
15 Pharmacology
|
|
| Description |
Background and aims Though cyclooxygenase inhibitors are employed in rheumatoid arthritis treatment, modulators of leukotrienes are underexplored. We investigated the therapeutic potential of montelukast, a known cysteinyl leukotriene receptor-1 (CysLT1) inhibitor in an experimental rat model of arthritis. Methods Arthritis was induced in rats, and montelukast (5 mg/kg body wt.) was administered prophylactically (PAM) and therapeutically (TAM) through oral route. Results and discussion Blood and joint tissue markers of oxidative stress (lipid peroxidation, protein carbonyls, and nitric oxides) were signifcantly (p |
|
| Date |
2020
|
|
| Type |
Article
PeerReviewed |
|
| Format |
pdf
|
|
| Language |
en
|
|
| Identifier |
http://ir.cftri.com/14625/1/Infammopharmacology%202019.pdf
Nayana, Venugopal and Pooja, Acharya and Ramaprasad, T. R. (2020) Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis. Infammopharmacology. |
|